Willow Biosciences Inc (ATLE) AI Stock Analysis

• Market Cap: C$55.65M
• Dividend Yield: N/A
• Average Volume (3M): 26.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: 26.91%
• EPS Growth: 81.01%
• Country: CA
• Employees: 19
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 352,222,660
• 10 Day Avg. Volume: 47,704
• 30 Day Avg. Volume: 26,236
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: C$0.18 ▲(14.37% Upside)

The overall stock score is primarily impacted by significant financial challenges, including negative equity and ongoing losses, which are major concerns. However, positive technical indicators and favorable corporate events provide some optimism for future performance.

Positive Factors

Revenue Growth

The significant revenue growth of 297.8% reflects strong demand for Willow's biosynthesis technology, indicating successful market penetration and potential for future expansion.

Gross Profit Margin

Achieving a 100% gross profit margin suggests effective cost management and the potential for sustainable profitability as the company scales its operations.

Innovative Business Model

Willow's focus on synthetic biology and biosynthesis positions it well in the growing biotech sector, leveraging innovation to meet increasing demand for sustainable production methods.

Negative Factors

Negative Equity

Negative equity indicates solvency issues, posing a risk to financial stability and limiting the company's ability to invest in growth opportunities.

Cash Flow Challenges

Persistent negative cash flow highlights liquidity challenges, potentially constraining the company's operational flexibility and ability to fund future growth.

Sustained Losses

Ongoing losses and negative profit margins indicate profitability challenges, which may hinder long-term financial health and investor confidence.

Willow Biosciences Inc Business Overview & Revenue Model

Company Description

Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and varin cannabinoids, such as cannabigerovarin, cannabidivarin, and tetrahydrocannabivarin. Willow Biosciences Inc. was incorporated in 1981 and is headquartered in Calgary, Canada.

How the Company Makes Money

Willow Biosciences Inc. generates revenue through several key streams. Primarily, the company monetizes its proprietary biosynthesis technology by entering into partnerships and licensing agreements with other companies in the pharmaceutical and nutraceutical sectors. These partnerships often involve co-development agreements where Willow provides its expertise in synthetic biology to help partners create and manufacture bioactive compounds. Additionally, Willow may sell its proprietary products directly to manufacturers looking for high-quality cannabinoids or other bioactive ingredients. The company may also earn revenue through research and development funding from collaborations with academic institutions or larger corporations seeking to innovate in the field of biosynthesis. Factors contributing to its earnings include the increasing demand for sustainable and efficient production methods in the biotech industry, as well as the growing acceptance and legalization of cannabinoids in various markets.

Willow Biosciences Inc Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Willow Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ATLE, the sentiment is Negative. The current price of 0.16 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.17, and below the 200-day MA of 0.17, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.74 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ATLE.

Willow Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DB	64 Neutral	C$60.57M	4.18	21.77%	―	15.11%	―
VEXT	59 Neutral	C$73.07M	-2.59	-21.73%	―	43.56%	-349.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATLE	50 Neutral	C$55.65M	-2.76	-19.76%	―	26.91%	81.01%
BNXT	48 Neutral	C$74.30M	-11.42	―	―	-62.34%	9.80%
IAN	44 Neutral	C$34.09M	20.00	―	―	-6.05%	―

Willow Biosciences Inc Corporate Events

Atlas Energy Corp. Expands Deal Pipeline Amid Favorable Market Conditions

Atlas Energy Corp. has released its unaudited consolidated interim financial statements for the third quarter of 2025, highlighting a favorable market environment for disciplined capital deployment due to moderated global oil prices and potential oversupply forecasts for 2026. This situation has expanded Atlas’s deal pipeline and improved the visibility of near-term opportunities, as the company continues to focus on acquiring high-quality assets operated by industry leaders to ensure robust cash flow and long-term value creation.